TESA / IPA Blend

The two peptides activate different receptor systems with complementary intracellular signaling. Tesamorelin agonizes the GHRH receptor (cAMP/PKA pathway), while ipamorelin activates GHS-R1a (PLC/IP3/Ca²⁺ pathway) and reduces somatostatin tone. Co-administration in preclinical models produces a greater-than-additive GH peak — useful for studying maximal somatotroph capacity in a single in vitro system.

Both pair a GHRH-class peptide with ipamorelin. CJC-1295 (DAC) is a tetrasubstituted GHRH(1-29) analog with a maleimide linker for albumin binding, giving it a multi-day half-life and a flat GH-axis "bleed." Tesamorelin is the full-length GHRH(1-44) with trans-3-hexenoyl modification — shorter half-life (~26 min) but better-defined Phase III clinical data on visceral adipose reduction. Researchers tend to choose CJC/IPA for sustained baseline elevation studies and TESA/IPA when modeling discrete pulsatile peaks aligned with full-length GHRH pharmacology.

In Raun et al. (1998), ipamorelin released GH in pigs and rats with a potency similar to GHRP-6 but without the concurrent ACTH, cortisol, or prolactin elevations characteristic of older GHRPs. This selectivity profile makes it preferable for research models attempting to isolate GHS-R1a-mediated effects from confounding HPA-axis activation.

Tesamorelin is a synthetic GHRH(1-44) analog with N-terminal trans-3-hexenoyl modification that protects against DPP-IV cleavage. Phase III data (Falutz et al. 2007, NEJM) demonstrated ~15-18% reduction in visceral adipose tissue and a near-doubling of IGF-1 in HIV-associated lipodystrophy at 26 weeks. FDA-approved as Egrifta in 2010.

Store the lyophilized vial at -20°C for long-term stability. Reconstitute with bacteriostatic water for research use; once reconstituted, refrigerate at 2-8°C and use within 14 days. Both peptides are sensitive to repeated freeze-thaw cycles and light. For in vitro research use only.

Tesamorelin holds FDA approval (Egrifta, 2010) for HIV-associated lipodystrophy. Ipamorelin was developed by Novo Nordisk and remained investigational — no marketing authorization was granted in the EU or US. This product is research-grade material supplied for in vitro use only.